Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Cooper, G. S., Bynum, M. L. K. & Somers, E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33, 197–207 (2009).
Hertz, D. L. & Rae, J. Pharmacogenetics of cancer drugs. Annu. Rev. Med. 66, 65–81 (2015).
Yang, W., Li, S. & Yang, Q. Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Medicine 98, e15731 (2019).
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017).
Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119–iv142 (2017).
Electronic Medicines Compendium (emc). https://www.medicines.org.uk/emc/. (2021).
Solinas, C. et al. Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer? Transl. Oncol. 13, 100811 (2020).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Wang, Y. et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 5, 1008–1019 (2019).
Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).
Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J. & Manne, A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front. Immunol. 13, 1–14 (2022).
Samani, A. et al. Impact of age on the toxicity of immune checkpoint inhibition. J. Immunother. Cancer 8, e000871 (2020).
Asada, M. et al. The risk factors associated with immune checkpoint inhibitor-related pneumonitis. Oncology 99, 256–259 (2021).
Triggianese, P. et al. Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun. Rev. 19, 102590 (2020).
Guzman-Prado, Y., Ben Shimol, J. & Samson, O. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol. Immunother. 70, 89–100 (2021).
Okada, N. et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci. Rep. 10, 13773 (2020).
Atchley, W. T. et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 160, 731–742 (2021).
Tang, S.-Q. et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res. Treat. 53, 339–354 (2021).
Ghisoni, E. et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur. J. Cancer 149, 153–164 (2021).
Marthey, L. et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory Bowel disease. J. Crohns. Colitis 10, 395–401 (2016).
Clotman, K., Janssens, K., Specenier, P., Weets, I. & De Block, C. E. M. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 3144–3154 (2018).
Calabrese, L. H., Calabrese, C. & Cappelli, L. C. Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569–579 (2018).
Nigro, O. et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study. Eur. J. Cancer 134, 19–28 (2020).
Khan, S. et al. Late‐onset immunotherapy toxicity and delayed autoantibody changes: checkpoint inhibitor-induced Raynaud’s‐like phenomenon. Oncologist 25, e753–e757 (2020).
Khan, S. A., Pruitt, S. L., Xuan, L. & Gerber, D. E. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2, 1507–1508 (2016).
Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2016).
Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).
Ricciuti, B. et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J. Cancer Res. Clin. Oncol. 145, 479–485 (2019).
Petrelli, F. et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J. Immunother. 43, 1 (2019).
Kirchhoff, T. & Ferguson, R. in Biomarkers for Immunotherapy of Cancer: Methods and Protocols (eds. Thurin, M., Cesano, A. & Marincola, F. M.) 93–117 (Springer New York, 2020).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Roederer, M. et al. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. Cell 161, 387–403 (2015).
Mangino, M., Roederer, M., Beddall, M. H., Nestle, F. O. & Spector, T. D. Innate and adaptive immune traits are differentially affected by genetic and environmental factors. Nat. Commun. 8, 13850 (2017).
Astle, W. J. et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167, 1415–1429.e19 (2016).
Nath, A. P. et al. Multivariate genome-wide association analysis of a cytokine network reveals variants with widespread immune, haematological, and cardiometabolic pleiotropy. Am. J. Hum. Genet. 105, 1076–1090 (2019).
Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).
Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511 (2003).
Zeissig, S. et al. Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut 64, 1889–1897 (2015).
Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661–673 (2013).
Vogelsang, M. et al. The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis. Clin. Cancer Res. 22, 3268–3280 (2016).
Gutierrez-Arcelus, M., Rich, S. S. & Raychaudhuri, S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat. Rev. Genet. 17, 160–174 (2016).
Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47, 1457–1464 (2015).
Cooper, J. D. et al. Seven newly identified loci for autoimmune thyroid disease. Hum. Mol. Genet. 21, 5202–5208 (2012).
Sirota, M., Schaub, M. A., Batzoglou, S., Robinson, W. H. & Butte, A. J. Autoimmune disease classification by inverse association with SNP alleles. PLOS Genet. 5, e1000792 (2009).
Gough, S. C. L. & Simmonds, M. J. The HLA region and autoimmune disease: associations and mechanisms of action. Curr. Genomics 8, 453–465 (2007).
Martin, M. A. & Kroetz, D. L. Abacavir pharmacogenetics—from initial reports to standard of care. Pharmacotherapy 33, 765–775 (2013).
Yamada, R. & Yamamoto, K. Mechanisms of disease: genetics of rheumatoid arthritis—ethnic differences in disease-associated genes. Nat. Clin. Pract. Rheumatol. 3, 644–650 (2007).
Chung, W.-H. et al. A marker for Stevens–Johnson syndrome. Nature 428, 486 (2004).
Lonjou, C. et al. A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharmacogenomics J. 6, 265–268 (2006).
Amstutz, U. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther. 103, 210–216 (2018).
White, C. et al. Ethnic diversity of DPD activity and the DPYD gene: review of the literature. Pharmgenomics. Pers. Med. 14, 1603–1617 (2021).
Chat, V. et al. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol. Immunother. 68, 897–905 (2019).
Simoncic, P. D., Lee-Loy, A., Barber, D. L., Tremblay, M. L. & McGlade, C. J. The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr. Biol. 12, 446–453 (2002).
Nomizo, T. et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients. Sci. Rep. 7, 45124 (2017).
Refae, S. et al. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest. N. Drugs https://doi.org/10.1007/s10637-019-00845-w (2019).
留言 (0)